Want to see AKTS full AI Analyst Report?
AKTS Stock Chart & Stats
$20.25
--
Market closed
$20.25
--
Day’s Range― - ―
52-Week Range$14.72 - $34.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.32B
Enterprise Value$896.56M
Total Cash (Recent Filing)$538.48M
Total Debt (Recent Filing)$11.58M
Price to Earnings (P/E)―
Beta2.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,404,617
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio3.39
Price to Book (P/B)-8.05
Price to Sales (P/S)181.08
P/FCF Ratio-15.96
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue175.90
Enterprise Value/Gross Profit201.70
Enterprise Value/Ebitda-27.92
Forecast
1Y Price Target
$35.50Price Target Upside75.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~596% revenue increase in 2025 versus 2024 signals meaningful commercial or clinical progress from a small base. Sustained top-line growth over the next several quarters would validate product-market traction, improving operational leverage and lowering burn per revenue dollar.
Strong Gross MarginReported strong gross margins indicate favorable unit economics for the core offering. If these margins persist as revenue scales, the company can narrow operating losses faster and improve incremental profitability, supporting a durable path toward break-even.
Modest Absolute DebtRelatively modest nominal debt keeps near-term default risk lower than highly levered peers. Lower interest obligations preserve cash flexibility, allowing management to prioritize R&D and commercialization while pursuing non-debt funding alternatives.
Bears Say
Large Net LossesVery large net losses materially erode retained capital and increase reliance on external funding. Persistent heavy losses reduce runway, raise dilution risk, and force management to prioritize near-term financing over long-term strategic investments, complicating execution.
Negative EquityDeeply negative shareholders’ equity reflects accumulated deficits and weak balance-sheet resilience. Negative equity can limit financing options, increase cost of capital, and signal structural solvency concerns that may impair strategic flexibility over the medium term.
Sharp Cash Burn ReversalA swing from positive FCF in 2024 to ~- $73.7M in 2025 shows cash generation is volatile and currently negative. Sustained negative free cash flow increases dependency on external capital, elevating execution and funding risk and potentially forcing program or commercialization trade-offs.
Aktis Oncology, Inc. News
AKTS FAQ
What was Aktis Oncology, Inc.’s price range in the past 12 months?
Aktis Oncology, Inc. lowest stock price was $14.72 and its highest was $34.19 in the past 12 months.
What is Aktis Oncology, Inc.’s market cap?
Aktis Oncology, Inc.’s market cap is $1.32B.
When is Aktis Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aktis Oncology, Inc.’s earnings last quarter?
Currently, no data Available
Is Aktis Oncology, Inc. overvalued?
According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued.
Does Aktis Oncology, Inc. pay dividends?
Aktis Oncology, Inc. does not currently pay dividends.
What is Aktis Oncology, Inc.’s EPS estimate?
Aktis Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aktis Oncology, Inc. have?
Aktis Oncology, Inc. has 53,404,617 shares outstanding.
What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aktis Oncology, Inc.?
Currently, no hedge funds are holding shares in AKTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aktis Oncology, Inc. Stock Smart Score
Company Description
Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
AKTS Stock 12 Month Forecast
Average Price Target
$35.50
▲(75.31% Upside)
Iovance Biotherapeutics
―
Zymeworks
―
Oric Pharmaceuticals
―
Immunocore Holdings
―
Nanobiotix
―
Ownership Overview
47.63% Insiders
4.33% Mutual Funds
0.08% Other Institutional Investors
44.25% Public Companies and
Individual Investors